Abstract
• Baricitinib, an anti-JAK1/JAK2, reduces cytokine release and SARS-Co-V2 entry. • In a retrospective multicenter study baricitinib reduces COVID-19 mortality rate. • Baricitinib reduces intensive care unit admissions of COVID-19 pneumonia. • Baricitinb reduces SARS-CoV-2 viral burden detected by nasopharyngeal swab. • Baricitinib used for 2 weeks was not associated with serious adverse events.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have